We are excited to announce ARMI’s active participation in the Tissue Engineering and Regenerative Medicine International Society (TERMIS-AM) 2025 Conference, a premier event bringing together global leaders in regenerative medicine. Mark your calendars for November 9-13, 2025, in Atlanta, GA, and join us for an inspiring lineup of sessions hosted by ARMI experts and visionaries.
Opening Plenary Symposium:
Dean Kamen, ARMI’s Executive Director, has been invited to speak during the Opening Plenary Symposium on Sunday, November 9, 2025, from 5:30 PM – 6:30 PM. Presentation Title: “Biomanufacturing: Moving Your Ideas from an Academic Lab Towards the Clinic” Dean will deliver a compelling 30-minute presentation on how to translate academic innovations into clinical applications, offering invaluable insights for researchers, innovators, and clinicians in the regenerative medicine field.
Featured Speaker:
Dr. Tom Bollenbach, ARMI’s Chief Technology Officer, will present groundbreaking advancements in tissue engineering and biomanufacturing, exploring the latest innovations driving the field forward.
Pre-Conference Workshop:
ARMI’s participation underscores our commitment to fostering collaboration and advancing innovation in tissue engineering and regenerative medicine. Don’t miss this opportunity to connect with ARMI thought leaders and be part of meaningful conversations shaping the future of healthcare.
For more information about TERMIS-AM 2025 and ARMI’s involvement, click here.
The Advanced Regenerative Manufacturing Institute (ARMI) is a member-based, nonprofit organization whose mission is to advance the bioeconomy of the United States.
BioFabUSA, a program of ARMI, is a public-private partnership with more than 170 members, including companies, academic institutions and not-for profit organizations.
ARMI BioIndustries is the full-service development and manufacturing operation within the Advanced Regenerative Manufacturing Institute.
NextFab is the first foundry for American biotechnology. The mission of NextFab is to produce technological solutions that help the United States protect against and respond to health-security threats, enhance daily medical care and add to the U.S. bioeconomy.
BioFabUSA, a program of ARMI, is a public-private partnership with more than 170 members, including companies, academic institutions and not-for profit organizations.
